₹7.5 0.0 0.0%
Last Trade - 11/11/03
| Market Cap | ÂŁn/a |
| Enterprise Value | ÂŁn/a |
| Revenue | ÂŁ175.5m |
| Position in Universe | th / 3096 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3,641 | 5,424 | 9,832 | 11,621 | 14,318 | 17,928 | +37.6% | ||||
| +30.6 | +27.2 | -22.8 | +82.6 | +45.8 | +12.0 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Arch Pharmalabs Ltd. is a pharmaceutical company. The Company is engaged in Products and Services business. Its Products business comprises manufacture and sale of active pharmaceutical ingredients (APIs) and Intermediates to generic pharmaceutical companies in both domestic and international markets. It offers Contract Research and Manufacturing Services (CRAMS). Its products include Atorvastatin calcium, which is a lipid lowering agent; Amlodipine besylate, which is a calcium channel blocker; Clopidogrel bisulphate (Form I and Form II), which is an anti-platelet agent, and Isosorbide-5-mononitrate, which is an anti anginal agent, among others. The Company has developed capabilities to provide a range of CRAMS starting from route selection/process development/optimization, analytical development, stability studies, safety studies, scale-up to technology transfer/clinical-trial manufacturing to commercial manufacturing to suit the United States/Europe regulatory requirements.
| Last Annual | March 31st, 2012 |
| Last Interim | January 1st, 1970 |
| Incorporated | April 2, 1993 |
| Public Since | October 17, 1994 |
| No. of Shareholders: | 18,699 |
| No. of Employees: | 2,355 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | Bombay Stock Exchange |
| Shares in Issue | 24,784,022 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | "H" Wing 4th Floor Tex Centre,Off Saki Vihar Road, Chandivali Andheri (E), MUMBAI, 400072, India |
| Web | http://www.archpharmalabs.com/ |
| Phone | +91 22 42871210 |
| Contact | () |
| Auditors | Chaturvedi & Shah |
As of 11/11/03, shares in Arch Pharmalabs are trading at ₹7.5, giving the company a market capitalisation of ÂŁn/a. This share price information is delayed by 15 minutes.
Shares in Arch Pharmalabs are currently trading at ₹7.5 and the price has moved by 0.552k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arch Pharmalabs price has moved by 0.390k% over the past year.
There are no analysts currently covering Arch Pharmalabs.
It is not known when Arch Pharmalabs will next release financial results.
Arch Pharmalabs does not currently pay a dividend.
Arch Pharmalabs does not currently pay a dividend.
Arch Pharmalabs does not currently pay a dividend.
To buy shares in Arch Pharmalabs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Arch Pharmalabs are currently trading at ₹7.5, giving the company a market capitalisation of ÂŁn/a.
Here are the trading details for Arch Pharmalabs:
We were not able to load our ranking data for Arch Pharmalabs
We were not able to load any forecast data for Arch Pharmalabs.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arch Pharmalabs. Over the past six months, the relative strength of its shares against the market has been 79.73%. At the current price of ₹7.5, shares in Arch Pharmalabs are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Arch Pharmalabs.
We were unable to find the directors for Arch Pharmalabs.
Here are the top five shareholders of Arch Pharmalabs based on the size of their shareholding:
